LabCorp Introduces Xcellerate COVID-19 Clinical Study Solution

LabCorp today announced that Covance, its drug development business, has deployed the Xcellerate COVID-19 solution as part of its award-winning Xcellerate platform. Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.

For more information, click here.